INTRODUCTION {#S1}
============

Loss of appetite as a result of inflammation, as well as the ability of immune cells to sense changes in circulating hormones and nutrient levels, suggests the existence of shared signaling pathways between immune and neuroendocrine systems ([@R2]; [@R5]). Accordingly, orexigenic peptides inhibit ([@R6]; [@R4]), while anorexigenic hormones promote, inflammation ([@R17]; [@R21]). First identified in a B cell line, nucleobindin-2 (NUCB2)/non-esterified fatty acids (NEFA) (for DNA-binding/EF-hand/acidic protein), is ubiquitously expressed in peripheral tissues and immune cells and is a calcium-binding protein that contains nuclear targeting signals, two helix-loop-helix regions with a concurrent EF-hand, and a leucine zipper motif ([@R18]; [@R15]). NUCB2 is encoded on chromosome 7F1, containing 14 exons in mice (chromosome 11 in human), with a genomic sequence of 36,186 bp. Post-transcription modifications lead to an mRNA sequence of 1,697 bp with a polypeptide 420 amino acids long. This protein then undergoes posttranslational modifications and is thought to be cleaved into three peptides, termed nesfatin-1, nesfatin-2, and nesfatin-3. Nesfatin-1, the 82-amino-acid peptide derived from Nucb2 protein, was found to reduce food intake by acting on an unknown receptor in the hypothalamus ([@R20]; [@R7]). Consistent with this, the vast majority of published studies on Nucb2 suggest that nesfatin-1-mediated anorexigenic effects on the hypothalamus are key drivers of the metabolic action of Nucb2.

In addition to the brain, NUCB2/nesfatin-1 is ubiquitously expressed in peripheral tissues, including the pancreas, adipose tissue, liver, kidney, and the gut ([@R7]). Such distribution implies that NUCB2/nesfatin-1 has important metabolic as well as immunologic functions. Pharmacological studies using administration of nesfatin-1 peptide suggest effects on glucose homeostasis, gastrointestinal function, water intake, temperature regulation, and sleep ([@R22]). Importantly, the presence of nesfatin-1 has been reported using commercial antibodies that have not been rigorously tested to discriminate full-length Nucb2 from its cleaved peptides ([@R24]). Although evidence from multiple studies supports that administration of nesfatin-1 peptide is biologically active, the validity of such a mechanism downstream of Nucb2 *in vivo* has been not been established in a physiological setting. Thus, the function of Nucb2 in various cell types remains unknown, and its mechanism of action in regulation of whole-body metabolism is also unclear. Here, through global, *Agrp*-neuron-specific, macrophage-specific, and adipocyte-specific deletion of Nucb2, we provide evidence that this protein regulates metabolic inflammation and insulin action but does not affect satiety.

RESULTS AND DISCUSSION {#S2}
======================

Given current evidence that Nucb2 inhibits feeding ([@R20]), we hypothesized that the anorexigenic protein Nucb2 might link the metabolic and immune systems by regulating inflammation. First, to understand whether *Nucb2* expression was regulated by age and/or diet, we analyzed *Nucb2* mRNA expression in 3-month-old and 6-month-old wild-type mice on either a low-fat diet or a high-fat diet (HFD). These analyses revealed that, upon HFD feeding, the hypothalamus, liver, and visceral adipose tissue (VAT) displayed no change in *Nucb2* expression ([Figures S1A](#SD1){ref-type="supplementary-material"}--[S1C](#SD1){ref-type="supplementary-material"}). Interestingly, 3 and 6 months of HFD feeding led to a significant increase in *Nucb2* expression in adipose tissue macrophages (ATMs) ([Figure 1A](#F1){ref-type="fig"}) and in adipose T cells ([Figure S1D](#SD1){ref-type="supplementary-material"}) isolated from the VAT. These data suggest a potential role of *Nucb2* in integrating host immunometabolic responses in conditions of chronic positive energy balance.

To gain definitive insights into the physiological roles of *Nucb2* in the regulation of food intake and immune-metabolic interaction, we generated mice harboring a floxed allele of the *Nucb2* gene ([Figures S1E](#SD1){ref-type="supplementary-material"}--[S1H](#SD1){ref-type="supplementary-material"}). Global deletion of *Nucb2* was achieved by breeding *Nucb2* floxed mice to those expressing Cre recombinase under the control of the EIIA promoter. This resulted in efficient loss of *Nucb2* protein and mRNA in hypothalamus, hippocampus, cortex, striatum, cerebellum, pituitary, and brown adipose and various white adipose tissues, as well as pancreas, liver, spleen, and thymus ([Figures 1B](#F1){ref-type="fig"} and [S2A](#SD1){ref-type="supplementary-material"}), without any overt phenotypes in knockout mice (data not shown) maintained on regular chow diet. In terms of cell-type specificity, the *Nucb2* was highly expressed in fibroblasts, adipose tissue T cells, B cells, and macrophages; and, as expected, the *Nucb2* mRNA was not detectable in the cells derived from the knockout (KO) mice ([Figures 1B](#F1){ref-type="fig"} and [S2B](#SD1){ref-type="supplementary-material"}). These data demonstrate that Nucb2 is widely expressed and that loss of Nucb2 does not induce any developmental defects in mice.

As Nucb2 contains nuclear targeting signals, we investigated the localization of Nucb2 in unstimulated and lipopolysaccharide (LPS)-activated murine embryonic fibroblasts (MEFs). The immunostaining confocal microscopy analyses revealed that Nucb2 protein was localized in the cytoplasm and did not translocate into nucleus upon LPS stimulation ([Figure 1C](#F1){ref-type="fig"}). Prior studies suggest that nesfatin-1 is the primary endocrine mediator of Nucb2's biological effects. Surprisingly, despite efficient deletion of the transcript and Nucb2 protein in mice, the commercial ELISAs used to detect nesfatin-1 appear to be non-specific, as no change in serum nesfatin-1 levels were detected in wild-type (WT) or global Nucb2-deficient mice ([Figure 1D](#F1){ref-type="fig"}). Further validation of the commercial nesfatin-1 ELISA using three different commercially available ELISA kits did not accurately detect nesfatin-1 peptide ([Figures S2C](#SD1){ref-type="supplementary-material"}--[S2F](#SD1){ref-type="supplementary-material"}). These results question the specificity of reagents used to ascribe the physiological function of endogenous nesfatin-1 peptide that is derived from *Nucb2*. Consistent with this, we found that global deletion of *Nucb2* had no effect on body weight and food intake in mice ([Figures S2G](#SD1){ref-type="supplementary-material"} and [S2H](#SD1){ref-type="supplementary-material"}), with no change in the orexigenic neuropeptide Agouti-related protein (AgRP) mRNA in the hypothalamus ([Figure S2I](#SD1){ref-type="supplementary-material"}). To definitively answer whether *Nucb2* is a regulator of food intake, we also deleted *Nucb2* from the AgRP orexigenic neurons in the hypothalamus. The deletion of *Nucb2* in AgRP neurons also had no effect on body weight and food intake ([Figure 1E](#F1){ref-type="fig"}) upon fasting and re-feeding and did not affect fasting blood glucose ([Figure 1F](#F1){ref-type="fig"}). It is plausible that previous studies ascribing anorexigenic function to *Nucb2* might result from supraphysiological doses of intracerebroventricularly injected synthetic nesfatin-1 peptide or short hairpin RNA injection ([@R19]), which may, indeed, be bioactive, but based on our data, this anorexigenic action appears irrelevant to Nucb2's physiological function and biology. Taken together, these results demonstrate that *Nucb2* is regulated by HFD in ATMs and T cells and that Nucb2 protein or its post-translationally processed peptides do not control food intake or body weight in mice.

Given that HFD increases *Nucb2* expression in ATMs, we next investigated the role of this gene in a model of diet-induced obesity (DIO). The control and *Nucb2^−/−^* mice fed an HFD displayed no significant difference in adipocyte size or fat mass ([Figures S2J](#SD1){ref-type="supplementary-material"}--[S2M](#SD1){ref-type="supplementary-material"}) and also had similar circulating levels of leptin and adiponectin ([Figures S2N](#SD1){ref-type="supplementary-material"} and [S2O](#SD1){ref-type="supplementary-material"}). When fed a chow diet and compared to control animals, *Nucb2^−/−^* mice showed no differences in whole-body insulin sensitivity, as measured by glucose infusion rate to maintain euglycemia during the entirety of the hyperinsulinemic-euglycemic clamp ([Figures S3A](#SD1){ref-type="supplementary-material"}--[S3F](#SD1){ref-type="supplementary-material"}) or plasma free fatty acids ([Figures S3H](#SD1){ref-type="supplementary-material"} and [S3I](#SD1){ref-type="supplementary-material"}). Despite high expression of *Nucb2* in pancreas ([Figures 1B](#F1){ref-type="fig"} and [S2A](#SD1){ref-type="supplementary-material"}), control and *Nucb2^−/−^* mice showed no difference in insulin production in both basal and clamped states in the chow-fed condition ([Figure S3G](#SD1){ref-type="supplementary-material"}). Interestingly, *Nucb2^−/−^* mice fed an HFD displayed significant whole-body insulin resistance, as reflected by an almost 50% decrease in the glucose infusion rate (21.3 ± 2.1 and 11.0 ± 0.9 for WT and *Nucb2^−/−^*, respectively; p = 0.002) required to maintain euglycemia during the hyperinsulinemic-euglycemic clamp ([Figures 2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}) without affecting insulin secretion ([Figure 2C](#F2){ref-type="fig"}). On the other hand, there was a significant increase in endogenous hepatic glucose output (EGP) in the obese *Nucb2^−/−^* clamped state but not in the basal state ([Figure 2D](#F2){ref-type="fig"}). Furthermore, compared to DIO WT mice, the *Nucb2^−/−^* animals fed an HFD had a significant increase in insulin-stimulated plasma free fatty acids (FFAs) ([Figure 2E](#F2){ref-type="fig"}). This resulted in an approximately 57% FFA suppression in WT mice and only a 2% suppression in the *Nucb2^−/−^* mice under clamped conditions, suggesting adipocyte dysfunction in the absence of *Nucb2* ([Figure 2F](#F2){ref-type="fig"}). Overall, these data show that the primary function of *Nucb2* is to sense a hyper-caloric HFD and control insulin sensitivity in conditions of chronic caloric excess.

To determine the mechanism of how *Nucb2* deficiency causes insulin resistance, we next examined the adipose tissue immune cells that are implicated in inducing inflammation and impairing insulin signaling ([@R11]; [@R23]; [@R16]; [@R14]). Surprisingly, despite severe insulin resistance in obese Nucb2-deficient mice, there was no increase in the frequency of ATMs and naive or effector and memory CD4 and CD8 cells in the VAT ([Figures 2G](#F2){ref-type="fig"}--[2J](#F2){ref-type="fig"}; [Figures S4A](#SD1){ref-type="supplementary-material"}--[S4F](#SD1){ref-type="supplementary-material"}). Therefore, we next determined whether *Nucb2* controls macrophage activation and inflammation. The bone-marrow-derived macrophages (BMDMs) deficient in *Nucb2* were differentiated *in vitro* using either LPS and interferon (IFN) γ or interleukin (IL)-4 to obtain pro-inflammatory (former "M1-like") or anti-inflammatory (former "M2-like") activation states, respectively. Interestingly, compared to WT control cells, the BMDMs lacking *Nucb2* displayed increased expression of the pro-inflammatory cytokines IL-1β, tumor necrosis factor alpha (TNF-α), and MIP-1α ([Figures 3A](#F3){ref-type="fig"}--[3C](#F3){ref-type="fig"}) in the IFNγ-activated macrophages, while no changes were detected in IL-4-activated cells. We confirmed these data *in vivo*, as the F4/80^+^ ATMs isolated from VAT of *Nucb2^−/−^* mice also displayed higher expression of IL-1β, TNFα, and MIP-1α ([Figures 3D](#F3){ref-type="fig"}--[3F](#F3){ref-type="fig"}). Furthermore, *Nucb2*-deficient BMDMs produced increased levels of active IL-1β (p17) protein ([Figure 3G](#F3){ref-type="fig"}) with higher nuclear factor κB (NFκB) activation ([Figure 3H](#F3){ref-type="fig"}) in response to Nlrp3 inflamma-some-dependent stimuli such as ATP, ceramides, or silica. Consistent with these data, inhibition of the NFκB pathway in *Nucb2*-deficient BMDMs abrogated the LPS-induced increased expression of IL-1β, TNFα, and MIP-1α ([Figures 3I](#F3){ref-type="fig"}--[3K](#F3){ref-type="fig"}). Together, these results demonstrate that loss of *Nucb2* increases macrophage inflammation in an NFκB-dependent mechanism.

We next sought to understand the mechanism of macrophage-mediated inflammatory response in obese mice that lack Nucb2. The F4/80^+^ macrophages from the VAT of obese WT and *Nucb2^−/−^* mice were sorted for whole transcriptome analysis by RNA sequencing (workflow in [Figure 4A](#F4){ref-type="fig"}). Principal-component analysis (PCA) revealed separate clusters of *Nucb2^−/−^* and WT ATMs ([Figure 4B](#F4){ref-type="fig"}), which was further supported by the hierarchical cluster analysis of the top 1,000 variable or differentially expressed (DE) genes ([Figure 4C](#F4){ref-type="fig"} and [4D](#F4){ref-type="fig"}). To further investigate the activation status of ATMs, linear support vector regression (SVR) was used to map the previously established multi-dimensional model of macrophage activation, reflected through 28 different activation states ([@R26]; [@R3]), onto the ATMs isolated from obese *Nucb2*-deficient and WT mice. These unbiased analyses revealed a surprisingly high heterogeneity of signatures in both WT and *Nucb2^−/−^* ATMs with no clear trend toward previously described pro-inflammatory ("M1-like") or anti-inflammatory ("M2-like") activation states ([Figure 4E](#F4){ref-type="fig"}). Moreover, the SVR analyses also demonstrate that when the transcriptome of macrophages activated by 28 different stimuli was overlaid with visceral ATMs *in vivo*, there were only minor differences between WT and *Nucb2^−/−^* macrophages in conditions of obesity ([Figure 4E](#F4){ref-type="fig"}). Together, these data demonstrate that, in conditions of metabolic inflammation, the models of macrophage activation and polarization induced in the presence of high levels of IFNγ and IL-4 produced during an active immune response do not inform about the status of ATM dysfunction seen in Nucb2-dependent insulin resistance.

It is now recognized that, depending upon the tissue of residence, macrophages display unique transcriptional signatures that reflect the local microenvironment and functionality of a particular organ ([@R13]; [@R9]; [@R3]). Consistent with these data, whole transcriptome analyses further revealed that, compared to control cells, the *Ncub2*-deficient ATMs display an enrichment of metabolic Gene Ontology (GO) terms, including upregulation of pentose phosphate pathway (PPP), glycolysis, one-carbon metabolism, and branched-chain amino-acid degradation ([Figure 4F](#F4){ref-type="fig"}). Given our prior findings that *Nucb2* controls pro-inflammatory cytokines via NFκB, we further mined the RNA sequencing (RNA-seq) data to determine whether NFκB-regulated inflammatory mediators were impacted by *Nucb2* deficiency in ATMs. This analysis, together with the search of existing databases, revealed that multiple pro-inflammatory NFκB regulatory genes (Table S1) were upregulated in *Nucb2^−/−^*, compared to WT, ATMs ([Figure 4G](#F4){ref-type="fig"}). These included Wdfy1, Fcna, and genes of the paired immunoglobulin (Ig)-like receptor A family (Pira) ([Figure 4G](#F4){ref-type="fig"}; Table S1). To determine the cell-autonomous regulation of insulin action by *Nucb2* in obesity, we specifically ablated *Nucb2* in myeloid-lineage cells (*Nucb2*^Mac−/−^) and adipocytes (*Nucb2*^Adip−/−^). Compared to control mice fed an HFD, ablation of *Nucb2* on macrophages or adipocytes had no impact on total body weight ([Figure 4H](#F4){ref-type="fig"}). Interestingly, compared to control mice fed an HFD, the loss of *Nucb2* in macrophages, but not adipocytes, significantly worsened the insulin action, as measured by glucose tolerance ([Figures 4I](#F4){ref-type="fig"} and [4J](#F4){ref-type="fig"}) and an insulin tolerance test ([Figures 4K](#F4){ref-type="fig"} and [4L](#F4){ref-type="fig"}). Taken together, these data demonstrate that nucleobindin-2 does not impact hypothalamic satiety mechanisms, as was previously reported, but instead controls macrophage-mediated metabolic inflammation to control insulin resistance in obesity.

Our studies demonstrate that the physiological function of NucB2 is to regulate insulin sensitivity in obesity. The *Nucb2*-deficient mice on an HFD demonstrate severe insulin resistance. Importantly, this defect in insulin action is not a reflection of increased obesity in Nucb2-deficient mice. The HFD has been shown to be associated with increased inflammation and inflammatory cytokine production ([@R11]; [@R25]). It is, therefore, plausible that macrophages and T cells respond by increasing production of *Nucb2* to try to dampen this inflammatory response. Our data suggest that macrophage Nucb2 deficiency increases metabolic inflammation and insulin resistance and reveals a homeostatic role of Nucb2 to regulate inflammatory cytokine production.

It has been previously shown that the EF-hand of Nucb2, as well as Nucb1, may also influence G protein signaling by binding to the Gα motif ([@R8]). Whether Nucb2 may influence G protein and calcium-dependent signaling in immune cells warrants further study. Also, given that Nucb2 is highly expressed in plasmacytoid dendritic cells (Immgen) and endocrine glands like pituitary and pancreas, future studies are required to determine the role of this protein in integrating host defense with hormone secretion.

Importantly, using multiple Cre-Lox-based mouse models, our results establish that Nucb2 is not involved in regulation of food intake. Thus, the prior results assigning function to Nucb2 should be re-evaluated, because of the limitations of approaches such as pharmacologic peptide/shRNA-based targeting to brain via ICV injections. In summary, our findings show that obesity-induced upregulation of *Nucb2* in macrophages may serve to sense energy excess that links control of inflammatory response to the regulation of insulin resistance.

STAR★METHODS {#S3}
============

CONTACT FOR REAGENT AND RESOURCE SHARING {#S5}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact Vishwa Deep Dixit (<vishwa.dixit@yale.edu>)

EXPERIMENTAL MODEL SYSTEMS {#S6}
--------------------------

All studies were approved by the Institutional Animal Care and Use Committees of Yale University and performed in accordance with NIH guidelines. Mice were generated within the transgenic core at Pennington Biomedical Research Center kept in a pathogen-free barrier facility maintained at 22--24°C with a 12:12-h dark-light cycle (lights on at 0700 h). Genetic targeting approach was used to create Nucb2 floxed allele by recombination of a PL253-loxP-frt-neo cassette to exon 3 in mouse embryonic stem cells. Once our vector was correctly designed and screened against neomycin for initial enrichment of the targeted clone, we used these embryonic stem cells for injection into blastocysts for the generation of heterozygous Nucb2-loxP floxed mice. These positive ES cells were used. Using polymerase chain reaction to genotype these neo-founder mice, we then removed the neomycin resistant drug marker by crossing to a recombinase FLP derived mouse which recognizes the flippase recognition target (FRT) for mediated cleavage and generation of our founder mice. We initially created a global KO by crossing floxed Nucb2 founder C57BL/6 mice with a global Ella-Cre driver to remove the floxed sequence.

Mice were housed up to 5 per cage and given ad-libitum access to normal chow (\#5002, at least 4.5% kcal crude fat, LabDiet), low fat diet (LFD; \#D12450B, 10% kcal as fat, Research Diets, New Brunswick, NJ) or a high fat diet (HFD; \#D12492i, 60% kcal as fat; Research Diets, New Brunswick, NJ) and sterilized water (Hydropac Alternative Watering System: Seaford, DE, USA). The mice were placed on the LFD or HFD at 6 weeks of age and maintained on it until death. All transgenic and WT mice were cross-fostered to parent cohorts in our colony and littermate controls males were randomly allocated to the different groups. The sentinel mice in our animal rooms were negative for currently tested standard murine pathogens (ectromelia, epizootic diarrhea of infant mice \[EDIM\], lymphocytic choriomeningitis \[LCMV\], Mycoplasma pulmonis, mouse hepatitis virus \[MHV\], murine norovirus \[MNV\], mouse parvovirus \[MPV\], murine minute virus \[MVM\], pneumonia virus of mice \[PVM\], reovirus type 3 \[REO3\], Theiler's murine encephalomyelitis virus \[TMEV\], and Sendai virus) at various times while the studies were performed. Changes in body weights were measured during the life of the animals. Fat mass (FM) and fat free mass were assessed by time-domain-nuclear magnetic resonance (Minispec Analyst AD; Bruker Optics, Silberstreifen, Germany) at different time points.

METHOD DETAILS {#S7}
--------------

### Hyperinsulinemic-euglycemic clamp {#S8}

Clamp studies were performed according to recommendations of the Mouse Metabolic Phenotyping Center Consortium ([@R1]). The clamp studies were performed on 14 week old, chow-fed mice, and on 12 week old mice (n = 8 WT, n = 7 Nucb2−/−) on a high fat diet for 6 weeks (n = 11 WT, n = 7 Nucb2−/−). After surgical implantation of an indwelling catheter in the right jugular vein, mice were allowed to recover for 7 days prior to the clamp experiments. Following an overnight 14-h fast, mice were infused with 3-\[3H\] glucose (HPLC purified; PerkinElmer Life Sciences, Waltham, Massachusetts) at a rate of 0.05 μCi/min for 120 min to determine basal glucose turnover. Next, a primed infusion of insulin and 3-\[3H\] glucose was administered for 4 min at rates of 7.14 milliunits·kg--1·min--1 and 0.24 μCi/min, respectively, after which the rates were reduced to 2.5 milliunits·kg--1·min--1 insulin for chow fed mice/3 milliunits·kg--1·min--1 insulin for HFD mice (Novolin; Novo Nordisk, Bagsværd, Denmark) and 0.1 μCi/min 3-\[3H\] glucose for the remainder of the experiment. Plasma samples were obtained from the tip of the tail at 0, 25, 45, 65, 80, 90, 100, 110, 120, 130, and 140 min for plasma glucose, insulin, and tracer levels. A variable infusion of 20% dextrose was given to maintain euglycemia (100-120 mg/dL). Also, mice received an i.v. albumin-containing solution mimicking artificial plasma (115 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl2-6H2O, 1.2 mM NaH2PO4-H2O, 1.2 mM Na2SO4, 2.5 mM CaCl-2H2O, 25 mM NaHCO3, and 4% BSA \[pH 7.4\]) at a rate of 4.2 μL/min, during the insulin-stimulated period of the clamp to compensate for volume loss secondary to blood sampling.

Glucose turnover was calculated as the ratio of the 3-\[3H\] glucose infusion rate to the specific activity of plasma glucose at the end of the basal infusion and during the last 40 min of the hyperinsulinemic-euglycemic clamp study. Hepatic glucose production represents the difference between the glucose infusion rate and the rate of glucose appearance. A 10-μCi bolus injection of 2-deoxy-d-\[14C\]-glucose was given at 90 min to determine tissue-specific glucose uptake, which was calculated from the area under the curve of 2-deoxy-d-\[14C\]-glucose detected in plasma and the tissue content of \[14C\]2-deoxyglucose-6-phosphate, as previously described. Following collection of the final blood sample, mice were anesthetized with an intravenous injection of 150 mg/kg pentobarbital, and tissues were harvested and frozen with aluminum forceps in liquid nitrogen. All tissues were stored at −80°C until later use.

### Tissue digestion and positive selection of T cells and macrophages {#S9}

Adipose tissue was digested using enzymatic digestion as previously described ([@R25]; [@R10]; [@R3]) Adipose tissue stromal vascular fraction cells were then collected, and T cells and macrophages were positively selected using CD3 and F4/80 labeled antibodies (Dynabeads, Life Technologies).

### Quantitative PCR {#S10}

RNA from tissue and cells was isolated using an RNeasy Plus mini and micro kit (QIAGEN; 74106 and 74034) according to the manufacturer's instructions. DNA digestion was performed on the columns to remove DNA using RNase-Free DNase according to manufacturer's instructions (79254; QIAGEN). Following RNA purification, samples were then used for iScript cDNA synthesis using a reverse transcriptase PCR kit (BIO-RAD; Hercules, CA, USA). Quantitative PCR was performed with the LightCycler 480 II (Roche Applied Science; Indianapolis, IN, USA) and Power SYBR Green detection reagent (Applied Biosystems by Thermo Fischer Scientific; Woolston Warrington, UK). Primer sequences for transcripts encoding proteins involved in lipid and glucose metabolism were designed with Primer Express Software.

In all qRT-PCR experiments, 25 ng cDNA was used. Fold induction of gene expression with Nucb2 was analyzed with the ΔΔCt method (also known as the comparative Ct method) as determined by the following equation: ΔΔCt = ΔCt treatment (age and diet) - ΔCt control (young/chow). Here, the ΔCt is the Ct value for the sample (Nucb2) normalized to the endogenous housekeeping gene GAPDH transcript.

### Western Blotting {#S11}

Tissues from WT and Nucb2−/− mice were prepared by grinding with mortar and pestle while kept frozen in liquid nitrogen followed by homogenization with RIPA buffer. Bone marrow derived macrophage cell lysates were prepared using RIPA buffer and immediately snap frozen in liquid nitrogen. Samples were vortexed every 10 min for 1 hr. Samples were centrifuged at 14,000 g for 15 min, the supernatant was collected and the protein concentration was determined using the DC Protein Assay (Bio-RAD). Antibodies to Nucb2 (1:1000, N6789; Sigma), IL-1β (1:500, GTX74034; Genetex), NFκB p65 (1:1,000 8242s, Cell Signaling), phosphorylated-NFκB p65 (1:1000 3033S, Cell Signaling), and β-actin (1:1,000 4967L; Cell Signaling) were used at the dilutions specified by the manufacturer. The immune complexes were visualized by incubation with horseradish peroxidase-conjugated anti-rat (PI31470; Pierce) or anti-rabbit secondary antibody (PI31460, Pierce). Immuno-reactive bands were visualized by enhanced chemiluminescence (PI32209; Pierce). Densitometry analysis was performed using the ImageJ Gel Analysis tool, where gel background was also removed individually for each band.

### Immunofluorescence microscopy {#S12}

WT and Nucb2−/− MEFs were plated on chamber slides 1 day before treatment. The following day cells were treated with LPS (1ug/ml) for 1 hr or non-treated for control. Cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100. After blocking with 10% BSA, the cells were stained with Nucb2 (AF6895; R&D Systems) followed by Donkey anti-Sheep IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 (Thermo Fisher Scientific), Alexa Fluor 594 Phalloidin (Thermo Fisher Scientific) for F-actin and DAPI (D9542; Sigma-Aldrich) for nucleus. The images were acquired on Leica TCS SP5 confocal microscope with 63x objective.

### Leukocyte quantification in adipose tissue {#S13}

Leukocytes were quantified in inguinal and epididymal fat pads using flow cytometry analysis as previously described by our laboratory ([@R25]; [@R10]; [@R3]). Cells were labeled using antibodies described below, and cells were run on a FACSCalibur (BD Biosciences, San Jose, CA, USA). Macrophage subsets were identified using F4/80, CD206 and CD11c antibodies (eBiosciences, San Diego, CA, USA and Biolegend, San Diego, CA, USA). T cell subpopulations were identified by CD3, CD4 and CD8 antibodies, while B cell populations were identified by B220 antibodies for B220, IgM and CD19 (eBiosciences). FACS data were analyzed by post-collection compensation using FlowJo software (Treestar Inc., Ashland, OR).

### Tissue Hematoxylin and Eosin (H&E) staining {#S14}

The adipose tissue and liver were collected from mice, fixed in 4% (vol/vol) buffered paraformaldehyde, embedded in paraffin and optimal cutting temperature (OCT) compound, then cut into 5 μm thick sections. Tissue sections were stained with hematoxylin and eosin (H&E). Fluorescent images of H&E-stained paraffin-sections were photographed using the Texas Red filter cube on an Axioplan 2 imaging microscope (Carl Zeiss Microscopy; Thornwood, NY, USA). Quantification of adipocyte size was measured using ImageJ image analysis software. The averages were found by measuring 15 adipocytes from 3 different sections from 4 different mice per group.

### Enzyme-linked immunosorbent assay (ELISA) {#S15}

The sera from mice were collected and stored at −80°C and used to quantify the concentration of Nucleobindin-2(Nucb2) in serum using the CUSABIO Mouse Nucb2 Elisa kit (CSB-EL016146MO). ELISAs were read on the Tecan Infinite M200 i-control. Nesfatin-1 was measured using nesfatin-1 (1-82aa) (rat) EIA kit (EK-003-22; Phoenix Pharmaceuticals; Burlingame, CA, USA) with a detectable range of 0.1-1000ng/ml. Adiponectin was measured using Mouse Adiponectin ELISA kit (EMD Millipore; St. Charles, Missouri, USA). Leptin was measured using Mouse/Rat Leptin Quantikine ELISA (R&D Systems; Minneapolis, MN, USA).

### RNA-Sequencing data generation {#S16}

Adipose tissue stromal vascular fraction cells were then collected, and macrophages were positively selected using F4/80 labeled antibodies (Dynabeads, Life Technologies). Optical density values of extracted RNA were measured using NanoDrop (Thermo Scientific) to confirm an A260:A280 ratio above 1.9. RNA integrity number (RIN) was measured using BioAnalyzer (Agilent) RNA 6000 Pico Kit to confirm RIN above 7.

Samples were run by the Yale Center for Genome Analysis using Clontech ultra low-input Library Prep Kit V2 (\#634899, Clontech Laboratories, Inc. Mountain View, CA, USA) and RNA-seq was performed as described previously ([@R3]). Samples were sequenced using single-end 1×75 on the Illumina HiSeq2500 (Illumina Biotechnology, San Diego, CA, USA). Read counts were normalized using DESeq2 (R-package) in collaboration with Life & Medical Sciences Institute at the University of Bonn. To avoid spurious fold changes during differential expression analysis, all normalized counts were set to a value of at least 1.

Raw fastq-files have been deposited at the Gene Expression Omnibus (GEO) database ([https://www.ncbi.nlm.nih.gov/geo/)](https://www.ncbi.nlm.nih.gov/geo/) and are available under the accession number GSE97309.

### Alignment and mRNA quantification of RNA-Seq data {#S17}

Raw fastq-files were aligned against the murine genome version mm10 using HISAT version 0.1.7-β ([@R12]) with all default options. The resulting BAM files were imported into Partek® Genomics Suite® software, version 6.6 Copyright©; 2017 (PGS). mRNA quantification was performed against the mm10-RefSeq Transcripts database version 2016-02-02 to obtain read counts for each individual RefSeq gene.

### Primary analysis of RNA-Seq data {#S18}

The obtained table containing read counts for 18,939 genes was normalized using DESeq2 and then imported back into PGS. Before further analyses, all normalized count values smaller than 1 were set to 1 to avoid spurious Fold-Changes later on. Then, the dataset was filtered down to expressed genes, by keeping those having an average normalized read count of at least 10 in at least one of the two investigated groups. The resulting 14,905 present genes were used as input for principal component analysis. In addition, the top 1000 most variable genes of those were displayed within a heatmap, where rows and columns were ordered by hierarchical clustering using Euclidean distance and average linkage.

### Visualization of differentially expressed genes {#S19}

Within a scatterplot, the log2-average expression across Nucb2 deficient and WT mice versus the log2-Fold-Change between Nucb2 deficient and WT mice was displayed for each of the 14,905 present genes. In addition, genes being significantly up- or downregulated determined using one-way ANOVA and requiring an unadjusted p value \< 0.05, were colored in red or blue, respectively.

### Comparison of Nucb2−/− and WT macrophages to human *in vitro* activated monocyte-derived cells {#S20}

To link the Nucb2−/− and WT macrophages to *in vitro* activated macrophages, the 14,905 present genes were used as input for CIBERSORT. As signature matrix, 29 macrophage subsets including inactivated human macrophages were used ([@R26]). To obtain a corresponding murine signature file, human symbols were translated to murine ones based on one-to-one orthologs, where non-matching genes were excluded from the signature. Based on linear support vector regression (SVR) using all default options, the relative fractions of the 29 macrophage subsets were determined for the Nubc2 deficient and WT ATMs.

### Detection of differentially expressed genes and pathways between Nucb2−/− and WT macrophages {#S21}

Using a one-way ANOVA and requiring an unadjusted p value \< 0.05 and a Fold-Change \> 2 or \< --2, 236 genes were identified to be up- and 83 to be downregulated in murine Nucb2−/− compared to WT macrophages, respectively. Using those genes separately as input for Partek Pathway, 22 pathways were identified to be up- and 8 to be downregulated in Nucb2−/− compared to WT mice, respectively using Fisher's Exact test.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S22}
---------------------------------------

We used a two-tailed Student's t test to examine differences between genotypes or treatments (age and feeding) with a p \< 0.05 considered statistically significant. The results are expressed as the arithmetic means ± SEM. Differences between means and different genetic model were determined by one-way ANOVA using Tukey's test, using SigmaStat or Graphpad Prism software, which protects the significance (p \< 0.05) of all pair combinations.

DATA AND SOFTWARE AVAILABILITY {#S23}
------------------------------

### Data Resources {#S24}

The accession number for the raw fastq-files for the RNA-seq analysis reported in this paper is GEO: GSE97309.
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![Nucleobindin-2 Is Not a Physiological Regulator of Food Intake\
(A) Real-time PCR analysis of *Nucb2* mRNA in F4/80^+^ visceral ATMs derived from mice fed a 60% HFD for 3 and 6 months (n = 6 per group; \*p\<0.05, \*\*p\<0.01.) ([Figure S1D](#SD1){ref-type="supplementary-material"}).\
(B) Immunoblot analysis of Nucb2 protein from different tissues of control and global Nucb2-deficient mice. The arrowhead on the left indicates the molecular weight of the Nucb2-specific band. NS, non-specific band. (See [Figures S2A](#SD1){ref-type="supplementary-material"} and [S2B](#SD1){ref-type="supplementary-material"} for mRNA expression in cells and organs of control and *Nucb2^−/−^* mice.)\
(C) Representative confocal microscopy images of mouse embryonic fibroblasts (MEFs) from WT (top) and *Nucb2^−/−^* (bottom) mice with (right) and without (left) treatment of 1 μg/mL LPS for 1 hr, labeled for Nucb2 (green), F-actin (red), and nucleus (blue). Scale bars, 50 μM.\
(D) ELISA of nesfatin-1 in plasma from WT and Nucb2-deficient mice and measurement of nesfatin-1 after the addition of 1,000 pg/mL peptide in plasma.\
(E) Body weight (left) and food intake (right) of WT and AgRP^Cre^Nucb2^−/−^ mice.\
(F) Food intake over 24 hr after fasting and refeeding (left) and blood glucose levels after fasting (right) in control and Agrp-neuron-specific Nucb2-deficient mice (n = 12 per group).\
See also [Figures S1D](#SD1){ref-type="supplementary-material"} and [S2](#SD1){ref-type="supplementary-material"}.](nihms-1503490-f0002){#F1}

![Elimination of Nucleobindin-2 Causes Insulin Resistance during Diet-Induced Obesity\
(A--F) Shown here: (A) the time course of glucose infusion rate in DIO WT and *Nucb2^−/−^* during hyperinsulinemic euglycemic clamp, (B) total glucose infusion rate, (c) basal and clamped plasma insulin levels, (D) basal and clamped endogenous hepatic glucose output, (E) basal and clamped plasma fatty acids, and (F) plasma fatty acid suppression during hyperinsulinemic euglycemic clamp in control and Nucb2-deficient mice fed an HFD for 6 months. All clamp data are represented as mean ± SEM (WT, n = 11; *Nucb2^−/−^* n = 8).\
(G and H) Fluorescence-activated cell sorting (FACS) quantification of (G) macrophage and (H) lymphocyte cell population frequencies in VAT from HFD-fed WT and *Nucb2^−/−^* mice.\
(I and J) FACS quantification of (I) CD4^+^ naive and effector and memory (EM) cell subsets and (J) CD8^+^ naive and effector and memory cell subsets in VAT from 8-month-old, HFD-fed WT and *Nucb2^−/−^* mice (WT, n = 5; Nucb2^−/−^ n = 8).\
\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.005. See also [Figure S4](#SD1){ref-type="supplementary-material"}.](nihms-1503490-f0003){#F2}

![Ablation of Nucleobindin-2 Promotes Inflammation in Macrophages in an NFκB-Dependent Manner\
Primary bone-marrow-derived macrophages (BMDMs) from WT and *Nucb2^−/−^* mice were treated with media alone for unpolarized macrophages; 1 μg/mL LPS plus 4 ng/mL interferon gamma IFNγ) to generate proinflammatory, former classically activated "M1-like" macrophages; or 1 ng/ml IL-4 to obtain anti-inflammatory, former alternatively activated "M2-like" macrophages.\
(A--C) Relative gene expression levels of (A) IL-1β, (B) TNFα, and (C) MIP-1α in control and Nucb2-deficient BMDMs. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.005. \*\*\*\*(D--F) Relative gene expression levels of (D) IL-1β, (E) TNFtα, and (F) MIP-1α in F4/80^+^ visceral adipose tissue sorted macrophages from obese, HFD-fed WT and *Nucb2^−/−^* mice. All data are represented as mean ± SEM (n = 4 per group). \*p \< 0.05, compared to WT.\
(G and H) Representative western blot analyses of (G) IL-1β (active p17) in the supernatant and (H) NFκB (p65) and phospho-NFκB in the cell lysates of BMDMs primed with LPS for 4 hr and stimulated with either ATP for 1 hr, ceramide for 6 hr, or silica for 5 hr in WT- or *Nucb2^−/−^*-derived cells.\
(I--K) Primary BMDMs from WT mice and *Nucb2^−/−^* mice were treated with media and 1 μg/mL LPS plus 4 ng/mL interferon gamma (IFNγ) to generate proinflammatory macrophages. Some macrophages were pretreated with Bay-11-7085 NFκB inhibitor. Displayed are the relative gene expression levels of (I) IL-1β, (J) TNFα, and (K) MIP-1α. All data are represented as mean ± SEM (n = 6 per group). \*p \< 0.05, compared to WT; \*\*p\<0.01, \*\*\*p\<0.005, \*\*\*\*p\<0.001.](nihms-1503490-f0004){#F3}

![Macrophage Intrinsic *Nucb2* Controls Whole-Body Insulin Resistance in Obesity by Regulating Inflammatory Tone in Adipose Tissue\
(A)The workflow of RNA-seq data analysis in (B)--(F).\
(B) Principal-component analysis (PCA) based on 14,905 present genes displaying ATMs derived from control and *Nucb2^−/−^* mice fed an HFD.\
(C) Heatmap depicting the top 1,000 most variable genes in Nucb2-deficient ATMs compared to control littermates. Z score of expression is scaled to a minimum of --2 and a maximum of 2. Rows and columns were ordered based on hierarchical clustering.\
(D) Scatterplot of log~2~ average expression (x axis) versus log~2~ fold change (y axis) between WT ATMs and ATMs lacking *Nucb2*. Genes being significantly up- or downregulated (unadjusted p \< 0.05) are indicated in red and blue, respectively. In addition, the top 20 up- or downregulated genes, ranked according to either fold change or expression in *Nucb2^−/−^* mice, were specifically labeled in black or brown, respectively.\
(E) Relative fractions of 29 different human *in-vitro*-activated macrophage subset gene signatures represented in WT ATMs or ATMs lacking *Nucb2*.\
(F) Pathways (blue indicates downregulated, and red indicates upregulated) in *Nucb2*-deficient ATMs.\
(G) Scatterplot depicting log~2~ expression values in WT mice(x axis), compared to *Nucb2^−/−^* mice (y axis), for NFκB-regulated genes (Table S1) significantly altered upon deletion of *Nucb2* in ATMs that promote inflammation.\
(H) Total body weight and glucose excursion and area under the curve after i.p. injection.\
(I--L) Glucose tolerance test (GTT; glucose levels in I and area under the curve in J) and insulin tolerance test (ITT; glucose levels in K and area under the curve in L) in control (*Nucb2*^fl/fl^), macrophage-specific (*Nucb2*^Mac−/−^), and adipocyte-specific (*Nucb2*^Adip−/−^) *Nucb2*-deficient mice fed an HFD for 6 weeks. n = 6--8 per group, \*p \< 0.05.\
See also Table S1.](nihms-1503490-f0005){#F4}

###### 

KEY RESOURCES TABLE

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  REAGENT or RESOURCE                             SOURCE                         IDENTIFIER
  ----------------------------------------------- ------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antibodies                                                                     

                                                                                 

  Anti-Mouse: Nucb2 (C-terminal)                  Sigma                          N6789\
                                                                                 RRID:AB_1854684

  Anti- Mouse/Rat Nesfatin-1/Nucleobindin-2       R&D Systems                    AF6895\
                                                                                 RRID:AB_10972964

  Anti-Mouse: IL-1β                               Genetex                        GTX74034\
                                                                                 RRID:AB_378141

  Anti-Mouse: NFκB p65                            Cell Signaling                 8242s\
                                                                                 RRID:AB_10859369

  Anti-Mouse: phosphorylated-NFκB p65             Cell Signaling                 3033s\
                                                                                 RRID:AB_331284

  Anti-Mouse: β-actin                             Cell Signaling                 4967L\
                                                                                 RRID:AB_330288

  F4/80                                           eBiosciences                   48-4801\
                                                                                 RRID:AB_1548747

  CD206                                           Biolegend                      141720\
                                                                                 RRID:AB_2562248

  CD11b                                           Biolegend                      45-0112\
                                                                                 RRID:AB_953560

  CD3                                             eBiosciences                   13-0037\
                                                                                 RRID:AB_1234956

  CD4                                             Biolegend                      100548\
                                                                                 RRID:AB_2563054

  CD8                                             eBiosciences                   12-0081\
                                                                                 RRID:AB_465530

  B220                                            eBiosciences                   13-0452\
                                                                                 RRID:AB_466450

  Alexa Fluor 488                                 Thermo Fisher Scientific       S11223\
                                                                                 RRID:AB_2336881

  Alexa Fluor 594 Phalloidin (F-actin)            Thermo Fisher Scientific       A12381\
                                                                                 RRID:AB_2315633

  DAPI                                            Sigma-Aldrich                  D9542

  horseradish peroxidase-conjugated anti-rat      Pierce                         PI31470

  horseradish peroxidase-conjugated anti-rabbit   Pierce                         PI31460

                                                                                 

  Biological Samples                                                             

                                                                                 

  Mouse: Tissues and cells                        This Paper/our animal models   N/A

                                                                                 

  Chemicals, Peptides, and Recombinant Proteins                                  

                                                                                 

  Glucose                                         Pierce                         PI32209

  Insulin                                         Eli Lilly                      Humulin R

  Chemiluminescence                               Pierce                         PI32209

  Bay-11-7085 NFκB inhibitor                      Sigma-Aldrich                  B5681

  recombinant nesfatin-1                          Phoenix Pharmaceuticals        003-22A

  Recombinant nesfatin-1 (1-29)                   Phoenix Pharmaceuticals        009-76

  recombinant nesfatin-2                          Phoenix Pharmaceuticals        009-73

  recombinant nesfatin-3                          Phoenix Pharmaceuticals        003-28

                                                                                 

  Critical Commercial Assays                                                     

                                                                                 

  Mouse Nucb2 Elisa kit                           CUSABIO                        CSB-EL016146MO

  nesfatin-1 (1-82aa) ELISA kit                   Phoenix Pharmaceuticals        EK-003-22

  Mouse/Rat Leptin Quantikine ELISA               R&D Systems                    MOB00

  Mouse Adiponectin ELISA kit                     EMD Millipore                  EZMADP-60K

  DC Protein Assay                                BIO-RAD                        5000111

                                                                                 

  Deposited Data                                                                 

                                                                                 

  Raw data files for RNA sequencing               NCBI Gene Expression Omnibus   GEO: GSE97309

                                                                                 

  Experimental Models: Cell Lines                                                

                                                                                 

  Mouse: Primary BMDM cells                       This Paper                     N/A

                                                                                 

  Experimental Models: Organisms/Strains                                         

                                                                                 

  Mouse: C57BL/6                                  The Jackson Laboratory         000664

  Mouse: Nucb2 fl/fl                              This Paper                     Generated by PBRC transgenic core

  Mouse: E11a-Cre                                 The Jackson Laboratory         011104

  Mouse: Adipoq-Cre                               The Jackson Laboratory         024671

  Mouse: LysM-Cre                                 The Jackson Laboratory         004781

  Mouse: AgRP-Cre                                 The Jackson Laboratory         012899

                                                                                 

  Oligonucleotides                                                               

                                                                                 

  Nucb2                                           This Paper                     N/A

  forward primer sequence                                                        

  5′-`AAAACCTTGGCCTGTCTGAA`-3′                                                   

  reverse primer                                                                 

  5′-`CATCGATAGGAACAGCTTCCA`-3′                                                  

  CCL4                                            This paper                     N/A

  forward primer sequence                                                        

  5′-`GAAACAGCAGGAAGTGGGAG`-3′                                                   

  reverse primer sequence                                                        

  5′-`CATGAAGCTCTGCGTGTCTG`-3′                                                   

  IL-1β                                           This Paper                     N/A

  forward primer sequence                                                        

  5′-`GGTCAAAGGTTTGGAAGCAG`-3′                                                   

  reverse primer sequence                                                        

  5′-`TGTGAAATGCCACCTTTTGA`-3′                                                   

  IL-6                                            This paper                     N/A

  forward primer sequence                                                        

  5′-`ACCAGAGGAAATTTTCAATAGGC`-3′                                                

  reverse primer sequence                                                        

  5′-`TGATGCACTTGCAGAAAACA`-3′                                                   

  TNFα                                            This paper                     N/A

  forward primer sequence                                                        

  5′-`AGGGTCTGGGCCATAGAACT`-3′                                                   

  reverse primer sequence                                                        

  5′-`CCACCACGCTCTTCTGTCTAC`-3′                                                  

  MIP-1α                                          This paper                     N/A

  forward primer sequence                                                        

  5′-`ACCATGACACTCTGCAACCA`-3′                                                   

  reverse primer sequence                                                        

  5′-`GTGGAATCTTCCGGCTGTAG`-3′                                                   

                                                                                 

  Software and Algorithms                                                        

                                                                                 

  ImageJ                                          BMC Bioinformatics             [https://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859-017-1934-z](https://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859–017-1934-z)

  FLOWJO                                          FlowJo LLC                     <https://www.flowjo.com/solutions/flowjo>

  SigmaPlot                                       Systat Software                [www.systatsoftware.com](http://www.systatsoftware.com/)

  SigmaSTAT                                       Systat Software                [www.systatsoftware.com](http://www.systatsoftware.com/)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Highlights

-   Ablation of Nucb2 does not control food intake and adiposity

-   Loss of Nucb2 increases inflammation and insulin resistance

-   Nucb2 does not induce leukocytosis in obesity

-   Macrophage-expressed Nucb2 drives insulin resistance
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